Lurbinectedin with atezolizumab maintenance therapy in . . . Small-cell lung cancer (SCLC) is one of the most lethal cancers, with patients diagnosed with extensive-stage small-cell lung cancer (ES-SCLC) experiencing a median survival of just 12 months after standard chemoimmunotherapy 1,2 The addition of immune checkpoint inhibitors such as atezolizumab1 or durvalumab2 to platinum-etoposide chemotherapy followed by immune checkpoint inhibitor
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage . . . The addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer resulted in significantly longer overall survival and progression-free survival than chemotherapy alone (Funded by F Hoffmann-La Roche Genentech; IMpower133 ClinicalTrials gov number, …
The Real-World Outcome of First Line Atezolizumab in . . . Keywords: Atezolizumab, Real-world, Small cell lung carcinoma Introduction Small cell lung cancer (SCLC) accounts for approximately 10%-15% of all lung cancers and shows rapid progression and poor prognosis relative to non-SCLC [1-3] Etoposide-containing platinum-based chemotherapy has shown high response rates for extensive-stage (ES) SCLC